Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial

Lancet

Volumn 366, Issue 9494, 2005, Pages 1367-1374

  Reich, Kristian ^a   Nestle, Frank O ^b   Papp, Kim ^c,d   Ortonne, Jean Paul ^e   Evans, Robert ^f   Guzzo, Cynthia ^g   Li, Shu ^g   Dooley, Lisa T ^g   Griffiths, Christopher E M ^h,i  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c PROBITY MEDICAL RESEARCH   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f SCIOS INC   (United States)

^g CENTOCOR INC   (United States)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INFLIXIMAB; LIVER ENZYME;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BLOOD TOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG FATALITY; DRUG INFUSION; DRUG RESPONSE; DRUG TOLERANCE; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; FEVER; HEADACHE; HERPES SIMPLEX; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; INFECTION; INJECTION SITE REACTION; JAUNDICE; MAINTENANCE THERAPY; MALE; MYALGIA; NAIL DISEASE; NEOPLASM; PAIN; PANCYTOPENIA; PATIENT; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; RHINITIS; SCORING SYSTEM; SKIN DEFECT; SQUAMOUS CELL CARCINOMA; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 26644433889     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67566-6     Document Type: Article

References (30)

1. M Lebwohl Psoriasis Lancet 361 2003 1197 1204
2. MP Schon, WH Boehncke Psoriasis N Engl J Med 352 2005 1899 1912
3. BJ Nickoloff, FO Nestle Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities J Clin Invest 113 2004 1664 1675
4. AB Gottlieb Psoriasis: emerging therapeutic strategies Nat Rev 4 2005 19 34
5. W Sterry, J Barker, WH Boehncke Biological therapies in the systemic management of psoriasis: International Consensus Conference Br J Dermatol 151 suppl 69 2004 3 17
6. O Boyman, HP Hefti, C Conrad, BJ Nickoloff, M Suter, FO Nestle Spontaneous development of psoriasis in a new animal model shows an essential role for resident T-cells and tumor necrosis factor-α J Exp Med 199 2004 731 736
7. C Bonifati, M Carducci, P Cordiali Fei Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony-stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity Clin Exp Dermatol 19 1994 383 387
8. BJ Nickoloff, GD Karabin, JNWN Barker Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis Am J Pathol 138 1991 129 140
9. M Kristensen, CQ Chu, DJ Eedy, M Feldmann, FM Brennan, SM Breathnach Localization of tumour necrosis factor-alpha (TNF-alpha) and its receptors in normal and psoriatic skin: epidermal cells express the 55-kD but not the 75kD TNF receptor Clin Exp Immunol 94 1993 354 362
10. K Reich, C Garbe, V Blaschke Response of psoriasis to interleukin-10 is associated with suppression of cutaneous type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation J Invest Dermatol 116 2001 319 329
11. A Mussi, C Bonifati, M Carducci Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis J Biol Regul Homeost Agents 11 1997 115 118
12. U Chaudhari, P Romano, LD Mulcahy, LT Dooley, DG Baker, AB Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial Lancet 357 2001 1842 1847
13. AB Gottlieb, R Evans, S Li, LT Dooley, C Guzzo, D Baker Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542
14. T Fredriksson, U Pettersson Severe psoriasis: oral therapy with a new retinoid Dermatologica 157 1978 238 244
15. P Rich, RK Scher Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis J Am Acad Dermatol 49 2003 206 212
16. SB Hanauer, CL Wagner, M Bala Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease Clin Gastroenterol Hepatol 2 2004 542 553
17. M Lebwohl, E Christophers, R Langley, JP Ortonne, J Roberts, CE Griffiths Alefacept Clinical Study Group: an international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis Arch Dermatol 139 2003 719 727
18. CL Leonardi, JL Powers, RT Matheson Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
19. M Lebwohl, SK Tyring, TK Hamilton A novel targeted T-cell modulator, efalizumab, for plaque psoriasis N Engl J Med 349 2003 2004 2013
20. KB Gordon, KA Papp, TK Hamilton Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial JAMA 290 2003 3073 3080
21. A Menter, K Gordon, W Carey Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis Arch Dermatol 141 2005 31 38
22. CL Leonardi, KA Papp, KB Gordon Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial J Am Acad Dermatol 52 2005 425 433
23. VMR Heydendael, PI Spuls, BC Opmeer Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 349 2003 658 665
24. ENBREL [package insert] 2003 Immunex Corporation Thousand Oaks, CA
25. M Bakleh, I Tleyjeh, EL Matteson, DR Osmon, EF Berbari Infectious complications of tumor necrosis factor-α antagonists Int J Derm 44 2005 443 448
26. D Khanna, M McMahon, DE Furst Safety of tumour necrosis factor-α antagonists Drug Safety 27 2004 307 324
27. R Maini, EW St Clair, F Breedveld Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial Lancet 354 1999 1932 1939
28. SB Hanauer, BG Feagan, GR Lichtenstein Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial Lancet 359 2002 1541 1549
29. Remicode (Inliximab). Physicians Desk Reference 2005 Medical Economics Company Montvale, USA
30. C Antoni, GG Krueger, K de Vlam Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial Ann Rheum Dis 64 2005 1150 1157